Effects of an anticarcinogenic bowman-birk protease inhibitor on purified 20S proteasome and MCF-7 breast cancer cells

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Souza, Larissa Da Costa ^a   Camargo, Ricardo ^a   Demasi, Marilene ^b   Santana, Jaime Martins ^a   De Sá, Cézar Martins ^a   De Freitas, Sonia Maria ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEASOME; PROTEASOME 20S; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CATALYSIS; CELL NUCLEUS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; DRUG TRANSPORT; ENZYME INHIBITION; ERYTHROCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGHT SCATTERING; MEMBRANE TRANSPORT; NONHUMAN; PH; TEMPERATURE;

ANIMALS; CHYMOTRYPSIN; ERYTHROCYTES; FABACEAE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HORSES; HUMANS; MCF-7 CELLS; MULTIPROTEIN COMPLEXES; PROTEASOME ENDOPEPTIDASE COMPLEX; TRYPSIN INHIBITORS;

EID: 84899959826     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086600     Document Type: Article

References (99)

1. Kato GJ. (1999) Human genetic diseases of proteolysis. Hum Mutat 13: 87-98.
2. Laskowski M, Kato I. (1980) Protein inhibitors of proteinases. Annu Rev Biochem 49: 593-626.
3. Ikenaka T, Norioka S. Bowman-Birk family serine proteinase inhibitors. In: Barrett A. J.; Salvesen, G. (eds). (1986) Proteinase Inhibitors, Wagenigen, Elsevier Science cap. 9: 361-371.
4. Laskowski M, Qasim MA. (2000) What can the structures of enzyme-inhibitor complexes tell us about the structures of enzyme substrate complexes? Biochem Biophys Acta 1477: 324-337. (Pubitemid 30119910)
5. De Leo F, Volpicella M, Licciulli F, Liuni S, Gallerani R, Ceci LR. (2002) PLANT-PIs: a database for plant protease inhibitors and their genes. Nucl Acids Res 30: 347-348. (Pubitemid 34679581)
6. Ascenzi P, Bocedi A, Bolognesi M, Spallarossa A, Coletta M, et al. (2003) The bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor): a milestone protein. Curr Protein & Peptide Sci 4: 231-251. (Pubitemid 36656736)
7. Joanitti GA, Freitas SM, Silva LP. (2006) Proteinaceous Protease Inhibitors: Structural Features and Multiple Functional Faces. Current Enzyme Inhibition 2(3): 199-217. (Pubitemid 44194423)
8. Mello MO, Tanaka AS, Silva-Filho MC. (2003) Molecular evolution of Bowman-Birk type proteinase inhibitors in flowering plants. Mol Phylogenet Evol 27: 103-112. (Pubitemid 36453116)
9. Kennedy AR. (1993) Overview: anticarcinogenic activity of protease inhibitors. In: Troll W.; Kennedy, A. R. (eds). Protease inhibitors as Cancer Chemopreventive agents. New York: Plenum Press p. 9-64.
10. Messina MJ, Persky V, Setchell KDR, Barnes S. (1994) Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 21: 113-131. (Pubitemid 24127628)
11. Messina M, Barnes S. (1991) The role of soy products in reducing risk of cancer. J Natl Cancer Inst 83: 541-546.
12. Kennedy AR. (1998) The Bowman-Birk inhibitor from soybean as an anticarcinogenic agent. Am J Clin Nutr 68: 1406-1412.
13. Kennedy AR. (1995) Prevention of Carcinogenesis by Protease Inhibitors. Cancer Research (Suppl.) 54: 1999-2005.
14. Joanitti GA, Azevedo RB, Freitas SM. (2010) Apoptosis and lysosome membrane permeabilization induction on breast cancer cells by an anticarcinogenic Bowman-Birk protease inhibitor from Vigna unguiculata seeds. Cancer Letters. 293: 73-81.
15. Clemente A, Sonnante G, Domoney C. (2011) Bowman-Birk inhibitors from legumes and human gastrointestinal health: current status and perspectives. Curr Protein Pept Sci 12 (5): 358-373.
16. Clemente A, Marín-Manzano MC, Jiménez E, Arques MC, Domoney C. (2012) The anti-proliferative effect of TI1B, a major Bowman-Birk isoinhibitor from pea (Pisum sativum L.), on HT29 colon cancer cells is mediated through protease inhibition. Br J Nutr 108, Suppl. 1: 135-144.
17. Armstrong WB, Kennedy AR, Wan XS, Taylor TH, Nguyen QA, et al. (2000) Clinical modulation of oral Leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 6: 4684-4691. (Pubitemid 32110405)
18. Richardson M. (1991). Seed storage proteins: the enzyme inhibitors. Meth Plant Biochem 5: 259-303.
19. Bode W, Huber R. (1992). Natural protein proteinase inhibitors and their interaction with proteinases. Eur J Biochem 204: 433-451.
20. Chen P, Rose J, Love R, Wei CH, Wang BC. (1992) Reactive Sites of an Anticarcinogenic Bowman-Birk Proteinase Inhibitor are Similar to Other Trypsin Inhibitors. The Journal of Biological Chemistry 267: 1990-1994.
21. Clemente A, Marín-Manzano MC, Arques MC, Domoney C. (2013) Bowman-Birk Inhibitors from Legumes: Utilization in Disease Prevention and Therapy, Bioactive Food Peptides in Health and Disease. Dr. Blanca Hernández-Ledesma (Ed.), ISBN: 978-953-51-0964-8, In Tech, DOI: 10.5772/51262. http://www.intechopen.com/books/bioactive-food-peptides-in- health-and-disease/bowman-birk-inhibitors-from-legumes-utilisation-in-disease- prevention-and-therapy.
22. Morhy L, Ventura MM. (1987) The complete amino acid sequence of the Vigna unguiculata (L.) WaLP seed trypsin and chymotrypsin inhibitor. An Acad Bras Cienc 59: 71-81.
23. Freitas SM, De Mello LV, Da Silva MC, Vriend G, Neshich G, et al. (1997) Analysis of the black-eyed pea trypsin and chymotrypsin inhibitor-α- chymotrypsin complex. FEBS Lett 409: 121-127. (Pubitemid 27273861)
24. Barbosa JARG, Silva LP, Teles RCL, Esteves GF, Azevedo RB, et al. (2007) Crystal Structure of the Bowman-Birk Inhibitor from Vigna unguiculata Seeds in Complex with b-Trypsin at 1.55 Å Resolution and Its Structural Properties in Association with Proteinases. Biophysical Journal 92: 1638-1650. (Pubitemid 46393475)
25. Ventura MM, Martin CO, Morhy L. (1975) A trypsin and chymotrypsin inhibitor from black-eyed pea (Vigna sinensis L.). VI. Isolation and properties of complexes with trypsin and chymotrypsin. An Acad Brasil Cienc 47: 335-346.
26. Xavier-Filho J, Ventura MM. (1988) Trypsin inhibitors in Cowpea: a review. Comments Agric Food Chem 1: 239-314.
27. Fachetti HCS, Mizuta K, Ventura MM. (1984) Thermodynamics of the black-eyed pea trypsin and chymotrypsin inhibitor. An Acad Bras Cienc 56: 311-317.
28. Freitas SM, Ikemoto H, Ventura MM. (1999) Thermodynamics of the binding of chymotrypsin with the black-eyed pea trypsin and chymotrypsin inhibitor (BTCI). J Protein Chem 18: 307-313. (Pubitemid 29293204)
29. Ventura MM, Xavier-Filho J. (1966) A trypsin and chymotrypsin inhibitor from black-eyed pea (V. Sinensis L.) I. Purification and partial characterization. An Acad Bras Ciênc 38: 553-566.
30. Silva LP, Leite JRSA, Bloch C, Freitas SM. (2001) Stability of a Black Eyed Pea Trypsin/Chymotrypsin inhibitor (BTCI). Protein and Peptide Lett 8: 33-38. (Pubitemid 32424685)
31. Franco OL, Santos RC, Batista JAN, Mendes ACM, Araújo A, et al. (2003) Effects of black-eyed pea trypsin/chymotrypsin inhibitor on proteolytic activity and on development of Anthonomus grandis. Phytochemistry 63: 343-349. (Pubitemid 36637357)
32. Carvalho AF, Santos-Neto MS, Monteiro HSA, Freitas SM, Morhy L, et al. (2008) BTCI enhances guanylin-induced natriuresis and promotes renal glomerular and tubular effects. Braz J Biol 68 (1): 149-154. (Pubitemid 351685099)
33. Silva LP, Azevedo RB, Morais PC, Ventura MM, Freitas SM. (2005) Oligomerization States of Bowman-Birk Inhibitor by Atomic Force Microscopy and Computational Approaches. Proteins: Structure, Function, and Bioinformatics 61: 642-648. (Pubitemid 41547420)
34. Esteves GF, Teles RCL, Calvacanti NS, Neves D, Ventura MM, et al. (2007) Crystallization, data collection and processing of the chymotrypsin-BTCI-trypsin ternary complex. Acta Cryst F63: 1087-1090. (Pubitemid 350225586)
35. Joanitti GA. Supervisors: Azevedo RB and Freitas SM. (2012) Ph thesis: Efeitos de extrato bruto de sementes de Vigna unguiculata e do inibidor de proteases BTCI, encapsulado em nanopartículas, no tratamento preventivo e terapêutico de câncer de mama e de pele, in vitro e in vivo. UnB-Depto de Morfologia.
36. Hortobagyi GN, De La Garza Salazar J, Pritchard K, Amadori D, Haidinger R, et al. (2005) The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 6: 391-401. (Pubitemid 43078894)
37. Dou QP, Li B. (1999) Proteasome inhibitors as potential novel anticancer agents. Drug Resist Updat 2 (4): 215-223. (Pubitemid 29526245)
38. Bochtler M, Ditzel L,M, Hartmann C, Huber R. (1999) The proteasome. Annu Rev Biophys Biomol Struct 28: 295-317. (Pubitemid 29319261)
39. Loidl G, Groll M, Musiol HJ, Huber R, Moroder L. (1999) Bivalency as a principle for proteasome inhibition. Proc Natl Acad Sci USA 96 (10): 5418-5422. (Pubitemid 29234632)
40. Glickman MH, Rubin DM, Fried VA, Finley D. (1998) The regulatory particle of the Saccharomyces cerevisiae proteasome. Mol Cell Biol 18: 3149-3162. (Pubitemid 28240488)
41. Voges D, Zwickl P, Baumeister W. (1999) The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 68: 1015-10168.
42. Pickart CM, Cohen RE. (2004) Proteasomes and their kin: proteases in the machine age. Nat Rev Mol Cell Biol 5: 177-187. (Pubitemid 38325799)
43. Hölzl H, Kapelari B, Kellermann J, Seemüller E, Sümegi M, et al. (2000) The regulatory complex of Drosophila melanogaster 26S proteasomes. Subunit composition and localization of a deubiquitylating enzyme. J Cell Biol 150 (1): 119-130.
44. Bossola M, Muscaritoli M, Costelli P, Grieco G, Bonelli G, et al. (2003) Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg 237: 384-389. (Pubitemid 38176454)
45. Groll M, Ditzel L, Lowe J, Stock D, Bochtler M, et al. (1997) Structure of 20S proteasome from yeast at 2.4 A u resolution. Nature 386: 463-471. (Pubitemid 27164066)
46. Kloetzel PM, Ossendorp F. (2004) Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 16: 76-81.
47. Blackburn C, Gigstad KM, Hales P, Garcia K, Jones M, et al. (2010) Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit.Biochem. J 430: 461-476.
48. Gavilán E, Sánchez-Aguayo I, Daza P, Ruano D. (2013) GSK-3b signaling determines autophagy activation in the breast tumor cell line MCF-7 and inclusion formation in the non-tumor cell line MCF-10A in response to proteasome inhibition. Cell Death and Disease 4: e572.
49. Wehenkel M, Ban JO, Ho YK, Carmony KC, Hong JT, et al. (2012) A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice. Br J Cancer 107: 53-62.
50. Park JE, Ao L, Miller Z, Kim K, Wu Y, et al. (2013) PSMB9 Codon 60 Polymorphisms Have No Impact on the Activity of the Immunoproteasome Catalytic Subunit B1i Expressed in Multiple Types of Solid Cancer. PLoS One 8(9): e73732.
51. Codony-Servat J, Tapia MA, Bosch M, Oliva C, Domingo-Domenech J, et al. (2006) Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 5 (3): 665-675.
52. An B, Goldfarb RH, Siman R, Dou QP. (1998) Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 5: 1062-1075. (Pubitemid 29008220)
53. Lopes UG, Erhardt P, Yao R, Cooper GM. (1997) p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 272 (20): 12893-12896. (Pubitemid 27216701)
54. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. (2003) The Proteasome as a Target for Cancer Therapy. Clinical Cancer Research 9: 6316-6325. (Pubitemid 38031815)
55. Chen YW, Huang S, Lin-Shiau S, LIN J. (2005) Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF-7 breast cancer cells through accumulation of MAP kinase phosphatase-1. Carcinogenesis 26 (7): 1296-1306. (Pubitemid 41417909)
56. Demasi M, Shringarpure R, Davies KJ. (2001) Glutathiolation of the proteasome is enhanced by proteolytic inhibitors. Arch Biochem Biophys 389 (2): 254-263. (Pubitemid 32881951)
57. Frisken BJ. (2001) Revisiting the method of cumulants for the analysis of dynamic light-scattering data. Applied Optics 40 (24): 4087-4091.
58. Hassan PA and Kulshreshtha SK. (2006) Modification to the cumulant analysis of polydispersity in quasielastic light scattering data. Journal of Colloid and Interface Science 300(2): 744-748. (Pubitemid 44036870)
59. Baldwin ET, Crumley KV, Carter CW. (1986) Practical, Rapid Screening of Protein Crystallization Conditions by Dynamic Light Scattering. Biophys J 49 (1): 47-48.
60. Tardioli S, Bonincontro A, Mesa CL, Muzzalupo R. (2010) Interaction of bovine serum albumin with gemini surfactants. Journal of Colloid and Interface Science 347 (1): 96-101.
61. Boehm K, Guddorf J, Albers A, Kamiyama T, Fetzner S, Hinz HJ. (2008) Thermodynamic Analysis of Denaturant-Induced Unfolding of HodC69S Protein Supports a Three-State Mechanism. Biochemistry 47: 7116-7126. (Pubitemid 351956360)
62. Carrotta R, Manno M, Giordano FM, Longo A, Portale G, et al. (2009) Protein stability modulated by a conformational effector: effects of trifluoroethanol on bovine serum albumin. Phys Chem. Chem Phys 11: 4007-4018.
63. Hanlon AD, Larkin MI, Reddick RM. (2010) Free-Solution, Label-Free Protein-Protein Interactions Characterized by Dynamic Light Scattering. Biophysical Journal 98: 297-304.
64. Lacerda SH, Park JJ, Meuse C, Pristinski D, Becker ML, et al. (2010) Interaction of gold nanoparticles with common human blood proteins. ACS Nano 4 (1): 365-379.
65. Liang L, Yao P, Gong J, Jiang M. (2004) Interaction of apo cytochrome c with sulfonated polystyrene nanoparticles. Langmuir 20 (8): 3333-3338.
66. Chen L, Tianqing L. (2008) Interaction behaviors between chitosan and hemoglobin. Int J Biol Macromol 42 (5): 441-446.
67. Libich DS, Hill CM, Bates IR, Hallett FR, Armstrong S, et al. (2003) Interaction of the 18.5-kD isoform of myelin basic protein with Ca2+-calmodulin: effects of deimination assessed by intrinsic Trp fluorescence spectroscopy, dynamic light scattering, and circular dichroism. Protein Sci 12 (7): 1507-1521. (Pubitemid 36759354)
68. Gokarn YR, Fesinmeyer RM, Saluja A, CAO S, Dankberg J, et al. (2009) Ion-specific modulation of protein interactions: Anion-induced, reversible oligomerization of a fusion protein. Protein Science 18: 169-179.
69. Shiba K, Niidome T, Katoh E, Xiang H, Han L, et al. (2010) Polydispersity as a Parameter for Indicating the Thermal Stability of Proteins by Dynamic Light Scattering. Analytical Sciences 26: 659.
70. Li S, Xing D, LI J. (2004) Dynamic Light Scattering Application to Study Protein Interactions in Electrolyte Solutions. Journal of Biological Physics 30: 313-324. (Pubitemid 40558065)
71. Kopp F, Steiner R, Dahlmann B, Kuehn L, Reinauer H. (1986) Size and shape of the multicatalytic proteinase from rat skeletal muscle. Biochim Biophys Acta 872 (3): 253-260. (Pubitemid 16049106)
72. Yoshimura T, Kameyama K, Takagi T, Ikai A, Tokunaga F, et al. (1993) Molecular characterization of the "26S" proteasome complex from rat liver. J Struct Biol 111 (3): 200-211.
73. Ventura MM, Mizuta K, Ikemoto H. (1981) Self-association of the black-eyed pea trypsin and chymotrypsin inhibitor in solution - a study by light-scattering. An Acad Bras Cienc 53: 195-201.
74. Lupas A, Koster AJ, Baumeister W. (1993) Structural features of 26S e 20S proteasomes. Enzyme Protein 47: 252-273.
75. Tanaka K, Yoshimura T, Kumatori A, Ichihara A, Ikai A, et al. (1988) Proteasomes (multi-protease complexes) as 20 S ring-shaped particles in a variety of eukaryotic cells. J Biol Chem 263 (31): 16209-16217. (Pubitemid 18262038)
76. Thomas AR, Oosthuizen V, Naudé RJ, Muramoto K. (2002) Purification and characterization of the 20S proteasome from ostrich skeletal muscle. Biol Chem 383 (7-8): 1267-1270. (Pubitemid 35215076)
77. Griffin TA, Nandi D, Cruz M, Fehling HJ, Kaer LV, et al. (1998) Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. J Exp Med 187: 97-104. (Pubitemid 28044824)
78. Orlowski M, Wilk S. (2000) Catalytic Activities of the 20S proteasome, a multicatalytic proteinase complex. Arch Biochem Biophys 383 (1): 1-16.
79. Groll M, Huber R. (2003) Substrate access and processing by the 20S proteasome core particle. Internat J Biochem 35: 606-616. (Pubitemid 36369509)
80. McBride JD, and Leatherbarrow RJ. (2001) Synthetic Peptide Mimics of the Bowman-Birk Inhibitor Protein Current Medicinal Chemistry 8: 909-917. (Pubitemid 32633549)
81. deBettignies G, Coux O. (2010) Proteasome inhibitors: dozens of molecules and still counting. Biochimie 92: 1530-45.
82. Kisselev AF, van der Linden WA, Overkleeft HS. (2012) Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol 19: 99-115.
83. Borissenko L, Groll M. (2007) 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem Rev 107: 687-717. (Pubitemid 46502369)
84. Kisselev AF, Kaganovich D, Goldberg AL. (2002) Binding of Hydrophobic Peptides to Several Non-catalytic Sites Promotes Peptide Hydrolysis by All Active Sites of 20S Proteasomes. J Biol Chem 277: 22260-22270.
85. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, et al. (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78: 761-771. (Pubitemid 24294452)
86. Pereira MEF, Chen WE, Li J, Johdo O. (1996) The Antitumor Drug Aclacinomycin A, Which Inhibits the Degradation of Ubiquitinated Proteins, Shows Selectivity for the Chymotrypsin-like Activity of the Bovine Pituitary 20 S Proteasome. J Biol Chem 271: 16455-16459. (Pubitemid 26238994)
87. Lee DH, Goldberg AL. (1998) Proteasome inhibitors: valuable new tools for cell biologists. Trends in Cell Biology 8: 397-403. (Pubitemid 28458705)
88. Craiu A, Gaczynska M, Akopian T, Gramm CF, Fenteany G, et al. (1997) Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem 272 (20): 13437-13445. (Pubitemid 27216779)
89. Heinemeyer W, Fischer M, Krimmer T, Stachon U, Wolf DH. (1997) The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing. J Biol Chem 272: 25200-25209. (Pubitemid 27415707)
90. Kisselev AF, Callard A, Goldberg AL. (2006) Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem 281 (13): 8582-8590. (Pubitemid 43847961)
91. Schmidtke G, Kraft R, Kostka S, Henklein P, Frömmel C, et al. (1996) Analysis of mammalian 20S proteasome biogenesis: the maturation of beta-subunits is an ordered two-step mechanism involving autocatalysis. The EMBO J 15: 6887-6898. (Pubitemid 27023260)
92. Groll M, Heinemeyer W, Jäger S, Ullrich T, Bochtler M, et al. (1999) The catalytic sites of 20S proteasomes and their role in subunit maturation: A mutational and crystallographic study, Proc Natl Acad Sci USA 96: 10976-10983. (Pubitemid 29487315)
93. Ghobrial IM, Witzig TE, Adjei AA. (2005) Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55 (3): 178-194. (Pubitemid 40826487)
94. Shen M, Schmitt S, Buac D, Ping Dou Q. (2013) Targeting the ubiquitin-proteasome system for cancer therapy. Expert Opin Ther Targets 17(9): 1091-1108.
95. Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ. (2004) Effects of the proteasome inhibitor Bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemo Ther Pharmacol 54 (4): 343-353. (Pubitemid 39304429)
96. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, et al. (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622. (Pubitemid 29269108)
97. Adams J. (2004) The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349-360.
98. Crawford LJ, Walker B, Ovaa H, Chauhan D, Anderson KC, et al. (2006) Comparative selectivity and specificity of the proteasome inhibitors BzLLLCO-CHO, PS-341, and MG-132. Cancer Res 66: 6379-6386.
99. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, et al. (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolentnon-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23: 676-684. (Pubitemid 46237441)